Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia

Oncology Reports

Volumn 27, Issue 2, 2012, Pages 461-466

  Li, Jie ^a,b   Xue, Liying ^a   Hao, Hongling ^b   Han, Yuxiang ^a   Yang, Jingci ^a   Luo, Jianmin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

4E BP1; Chronic myelogenous leukemia; mTOR; P70S6K

Indexed keywords

CASPASE 3; CYCLIN D1; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P21; RAPAMYCIN; S6 KINASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84862940943     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1502     Document Type: Article

References (26)

1. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652, 2002. (Pubitemid 34815868)
2. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003. (Pubitemid 36302244)
3. Hess G, Meyer RG, Schuch B, Bechthold K, El-Kholy I and Huber C: Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow-up. Am J Hematol 83: 178-184, 2008. (Pubitemid 351303939)
4. Mancini M, Corradi V, Petta S, Martinelli G, Barbieri E and Santucci MA: mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res 34: 641-648, 2010.
5. Ly C, Arechiga AF, Melo JV, Walsh CM and Ong ST: Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63: 5716-5722, 2003. (Pubitemid 37187466)
6. Mohi MG, Boulton C, Gu TL, et al: Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101: 3130-3135, 2004. (Pubitemid 38327746)
7. Parmar S, Smith J, Sassano A, et al: Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106: 2436-2443, 2005. (Pubitemid 41510818)
8. Foster KG and Fingar DC: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077, 2010.
9. Wang ZG, Fukazawa T, Nishikawa T, et al: RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep 23: 1167-1172, 2010.
10. Mishra R, Miyamoto M, Yoshioka T, et al: Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Int J Oncol 34: 1231-1240, 2009.
11. Johnston PB, Inwards DJ, Colgan JP, et al: A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85: 320-324, 2010.
12. Nagai T, Ohmine K, Fujiwara S, Uesawa M, Sakurai C and Ozawa K: Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. Leuk Res 34: 1057-1063, 2010.
13. Abraham RT and Gibbons JJ: The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13: 3109-3114, 2007. (Pubitemid 46944891)
14. Hirase C, Maeda Y, Takai S and Kanamaru A: Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leuk Res 33: 450-459, 2009.
15. Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM and Cardoso AA: Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 39: 457-472, 2011.
16. Weisberg E, Banerji L, Wright RD, et al: Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 111: 3723-3734, 2008.
17. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
18. Pyronnet S and Sonenberg N: Cell-cycle-dependent translational control. Curr Opin Genet Dev 11: 13-18, 2001. (Pubitemid 32119272)
19. Harada H, Andersen JS, Mann M, Terada N and Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98: 9666-9670, 2001. (Pubitemid 32769360)
20. Meyuhas O: Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 267: 6321-6330, 2000.
21. Yang J, Ikezoe T, Nishioka C, Ni L, Koeffler HP and Yokoyama A: Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. Exp Hematol 38: 666-676, 2010.
22. Yazbeck VY, Buglio D, Georgakis GV, et al: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36: 443-450, 2008. (Pubitemid 351384743)
23. Mayerhofer M, Aichberger KJ, Florian S, et al: Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF suppressive effects of rapamycin in leukemic cells. FASEB J 19: 960-962, 2005. (Pubitemid 40827717)
24. Mayerhofer M, Valent P, Sperr WR, Griffin JD and Sillaber C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1á, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100: 3767-3775, 2002. (Pubitemid 35303950)
25. Gera JF, Mellinghoff IK, Shi Y, et al: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279: 2737-2746, 2004. (Pubitemid 38114263)
26. Vega F, Medeiros LJ, Leventaki V, et al: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66: 6589-6597, 2006. (Pubitemid 44085614)